2006
DOI: 10.1097/01.pec.0000230550.79046.68
|View full text |Cite
|
Sign up to set email alerts
|

Impact of the Pneumococcal Conjugate Vaccine in the Management of Highly Febrile Children Aged 6 to 24 Months in an Emergency Department

Abstract: Inclusion of PCV-7 vaccinal status in the management of highly febrile children aged 6 to 24 months significantly reduces CBC and blood cultures practiced in the ED and the administration of ceftriaxone.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
8
0
1

Year Published

2008
2008
2018
2018

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 17 publications
(10 citation statements)
references
References 19 publications
1
8
0
1
Order By: Relevance
“…In well‐appearing children 3–36 months of age with FWS, overall OB rates <0.5% were found in studies with general population PCV‐7 coverage of approximately 80% (10,12), while rates between 0.7% and 0.9% were found in the studies carried out in the Basque Country in Spain (13–15), where PCV‐7 coverage in the general population was lower (50–70%) and patients included in the study were mostly unvaccinated (study subjects who received at least 1 PCV‐7 dose represented 27% and 11%, respectively, in two of these studies) (14,15). In the Spanish PED, PCV‐7 introduction was associated with an important reduction in blood tests performance for vaccinated children (19). The study including only infants younger than 3 months of age showed an overall bacteremia rate of 2.2% with no SP cases; bacteremia was found more frequently in patients considered ‘not well appearing’ and in those with leukocyturia and/or nitrituria (16).…”
Section: Resultsmentioning
confidence: 99%
“…In well‐appearing children 3–36 months of age with FWS, overall OB rates <0.5% were found in studies with general population PCV‐7 coverage of approximately 80% (10,12), while rates between 0.7% and 0.9% were found in the studies carried out in the Basque Country in Spain (13–15), where PCV‐7 coverage in the general population was lower (50–70%) and patients included in the study were mostly unvaccinated (study subjects who received at least 1 PCV‐7 dose represented 27% and 11%, respectively, in two of these studies) (14,15). In the Spanish PED, PCV‐7 introduction was associated with an important reduction in blood tests performance for vaccinated children (19). The study including only infants younger than 3 months of age showed an overall bacteremia rate of 2.2% with no SP cases; bacteremia was found more frequently in patients considered ‘not well appearing’ and in those with leukocyturia and/or nitrituria (16).…”
Section: Resultsmentioning
confidence: 99%
“…The PCV7 has not been included in the official vaccination schedule of the public health system of the Basque Country, and was only dispensed in private practice. Its use had progressively increased from 2002, with a vaccine coverage rate in children under 2 years of age estimated to be close to 50% before 2006 [10]) and 60% in 2009, based on the number of doses sold in Gipuzkoa.…”
Section: Methodsmentioning
confidence: 99%
“…Population data were based on the official censuses for 1991, 1996, 2001 and 2006 (Eustat, http://www.eustat.es). The PCV7 was introduced in Spain in June 2001 and approximately 50% of children aged <2 years have been vaccinated in the study region [6].…”
Section: Temporal Distribution Of Streptococcus Pneumoniae Serotype mentioning
confidence: 99%